

REMARKS

This Preliminary Amendment is being made upon entry of International Application No. PCT/EP04/003783 into the U.S. National Phase of prosecution.

An abstract on a separate sheet is attached as required under 37 CFR § 1.72(b). Claim 1 has been amended to more specifically define the point of attachment of the carboxylic acid group to R¹. Support for this amendment can be found in the specification at page 3, lines 21-25. No new matter is added. Claims 3-4, 6-7 and 10-11 have been amended to eliminate multiple dependencies and to comply with proper U.S. claim format. Claims 8 and 9 have been cancelled. Entry of this amendment into the record is requested.

Respectfully submitted,





James C. Kellerman
Attorney for Applicants
Registration No. 43,708

GLAXOSMITHKLINE
Corporate Intellectual Property UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5929
Facsimile (610) 270-5090

N:\jck\cases\pb60052\prelimamend

ABSTRACT OF THE DISCLOSURE

Pleuromutilin compounds of the formula:



are of use in antibacterial therapy.